AstraZeneca Agrees to Lower Prescription Drug Prices for Medicaid
In a significant development, AstraZeneca has become the second major pharmaceutical manufacturer to announce a deal with the Trump administration to lower the cost of prescription drugs for Medicaid. This agreement comes after Pfizer announced a similar deal last month. According to President Donald Trump, AstraZeneca will charge most-favored-nation pricing to Medicaid, ensuring that the prices of their drugs are matched to the lowest prices offered in other developed nations.
Details of the Agreement
Under the terms of the agreement, AstraZeneca will guarantee most-favored-nation pricing on newly launched drugs, which could potentially lead to significant price reductions for Americans. Trump stated that this deal may result in the lowest prices for prescription drugs anywhere in the world. AstraZeneca’s CEO, Pascal Soriot, acknowledged that the negotiations were tough, with Trump and his team keeping him “up at night” to reach a deal.
The agreement is seen as a major win for the Trump administration, which has been working to reduce the cost of prescription drugs in the US. The administration had threatened to impose steep tariffs on pharmaceutical companies that did not agree to lower their prices. AstraZeneca’s deal is expected to have a significant impact on the prices of their cancer treatments, including Tagrisso, Lynparza, and Calquence, which generated over $7.5 billion in US sales last year.
Investments and Job Creation
AstraZeneca also announced plans to invest $4.5 billion in a new manufacturing plant near Charlottesville, Virginia, which is expected to create thousands of jobs. The company plans to make $50 billion in investments in the US by 2030, with the goal of reaching $80 billion in total revenue, half of which will be generated in the US. Trump predicted that these investments could lead to the creation of 3,600 jobs domestically, “just to begin with.”
The Trump administration has also launched a new website, TrumpRX.gov, which will allow people to buy drugs directly from manufacturers, including Pfizer and AstraZeneca. The website is expected to go live in January 2026 and will provide a platform for Americans to access affordable prescription drugs.
For more information on this development, please visit Here
Image Source: www.twincities.com
